CN1286831C - 作为ccr－3受体拮抗剂ⅷ的n－脲基－哌啶类化合物 - Google Patents

作为ccr－3受体拮抗剂ⅷ的n－脲基－哌啶类化合物 Download PDF

Info

Publication number
CN1286831C
CN1286831C CNB028239784A CN02823978A CN1286831C CN 1286831 C CN1286831 C CN 1286831C CN B028239784 A CNB028239784 A CN B028239784A CN 02823978 A CN02823978 A CN 02823978A CN 1286831 C CN1286831 C CN 1286831C
Authority
CN
China
Prior art keywords
alkyl
phenyl
chlorobenzyl
piperidin
trans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028239784A
Other languages
English (en)
Chinese (zh)
Other versions
CN1599733A (zh
Inventor
黛西·乔·杜波依斯
丹尼斯·约翰·凯尔泰斯
埃瑞克·布莱恩·肖格伦
戴维·伯纳德·史密斯
王北汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1599733A publication Critical patent/CN1599733A/zh
Application granted granted Critical
Publication of CN1286831C publication Critical patent/CN1286831C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNB028239784A 2001-11-30 2002-11-25 作为ccr－3受体拮抗剂ⅷ的n－脲基－哌啶类化合物 Expired - Fee Related CN1286831C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33465301P 2001-11-30 2001-11-30
US60/334,653 2001-11-30

Publications (2)

Publication Number Publication Date
CN1599733A CN1599733A (zh) 2005-03-23
CN1286831C true CN1286831C (zh) 2006-11-29

Family

ID=23308166

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028239784A Expired - Fee Related CN1286831C (zh) 2001-11-30 2002-11-25 作为ccr－3受体拮抗剂ⅷ的n－脲基－哌啶类化合物

Country Status (12)

Country Link
EP (1) EP1453825A1 (https=)
JP (1) JP2005515193A (https=)
KR (1) KR100652450B1 (https=)
CN (1) CN1286831C (https=)
AR (1) AR037458A1 (https=)
AU (1) AU2002352123A1 (https=)
BR (1) BR0214613A (https=)
CA (1) CA2467874A1 (https=)
MX (1) MXPA04005176A (https=)
PL (1) PL370821A1 (https=)
RU (1) RU2004120064A (https=)
WO (1) WO2003045937A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558599A4 (en) * 2002-10-30 2007-06-27 Merck & Co Inc HETEROARYLPIPERIDINE MODULATORS DERCHEMOKIN RECEPTORACTIVITY
EP1640361B9 (en) * 2003-06-30 2015-11-04 Sumitomo Chemical Company, Limited Asymmetric urea compounds and process for producing asymmetric compounds by asymmetric conjugate addition reaction using the same as catalyst
WO2005058805A1 (ja) * 2003-12-17 2005-06-30 Sumitomo Chemical Company, Limited 光学活性アミン化合物の製造方法
WO2006071958A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP2805985A1 (de) * 2013-05-22 2014-11-26 Sika Technology AG Hydroxysilan und Silangruppen-haltiges Polymer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69926806D1 (de) * 1998-12-18 2005-09-22 Bristol Myers Squibb Pharma Co N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren

Also Published As

Publication number Publication date
CA2467874A1 (en) 2003-06-05
EP1453825A1 (en) 2004-09-08
AR037458A1 (es) 2004-11-10
AU2002352123A1 (en) 2003-06-10
KR20040062665A (ko) 2004-07-07
CN1599733A (zh) 2005-03-23
WO2003045937A1 (en) 2003-06-05
RU2004120064A (ru) 2006-01-10
MXPA04005176A (es) 2004-08-11
PL370821A1 (en) 2005-05-30
BR0214613A (pt) 2004-09-14
JP2005515193A (ja) 2005-05-26
KR100652450B1 (ko) 2007-02-28

Similar Documents

Publication Publication Date Title
CN1107061C (zh) 趋化细胞因子受体－3拮抗剂
CN1158256C (zh) 吡咯烷衍生物-ccr-3受体拮抗剂
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1187342C (zh) 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN1303067C (zh) 用作半光氨酸蛋白酶可逆抑制剂的螺杂环腈
CN1148367C (zh) 新的脒衍生物,其制备方法,其作为药物的用途以及含有该化合物的药物组合物
CN100337626C (zh) 酰化的、杂芳基－稠合的环烯基胺和它们作为药物的用途
CN1084743C (zh) 毒蕈碱拮抗剂
CN1585749A (zh) 类大麻苷受体配体
CN1178922C (zh) 取代的1-氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN101080226A (zh) 酰氨基化合物及它们作为药物的用途
CN1633414A (zh) 化合物
HK1048306B (zh) 药学活性磺酰胺衍生物
CN1143848C (zh) 用作毒蕈碱性受体拮抗剂的2-芳基乙基-(哌啶-4-基甲基)胺衍生物
CN1471536A (zh) 趋化因子受体拮抗剂及其使用方法
CN1617869A (zh) 作为尿压素ⅱ受体拮抗剂的4－(哌啶基－吡咯烷基－烷基－脲基)－喹啉类化合物
CN1308324C (zh) 作为α－1肾上腺素能拮抗剂的喹唑啉衍生物
CN1732158A (zh) 作为促肾上腺皮质激素释放因子拮抗剂的吲唑衍生物
CN1753891A (zh) Ccr－3受体拮抗剂
CN1610678A (zh) 吡咯烷酮羧酰胺
CN1599722A (zh) 作为毒蕈碱受体拮抗剂的4－哌啶基烷基胺衍生物
CN1286831C (zh) 作为ccr－3受体拮抗剂ⅷ的n－脲基－哌啶类化合物
CN1599611A (zh) 作为哮喘治疗中的ccr－3受体拮抗剂的哌嗪衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee